Literature DB >> 19522763

Functionally active toll-like receptor 3 on human primary and metastatic cancer cells.

T Matijevic1, M Marjanovic, J Pavelic.   

Abstract

Toll-like receptor 3 (TLR3) is a member of Toll-like receptors who recognize structurally conserved molecules derived from pathogens and trigger the immune response. To clarify if TLR3, is expressed in certain tumour cell lines and whether it is functional and what is the response of these cell lines to different concentrations of poly I:C treatment, we have screened SW480, SW620, FaDu and Detroit 562 cell lines using real-time PCR, flow cytometry and ELISA. We have shown that all these cell lines express TLR3 on mRNA and protein level but it is only functional in Detroit 562 cell line since only in these cells poly I:C treatment triggered the IL-6 secretion. In addition, poly I:C treatment inhibited cell growth and triggered up-regulation of IL-12p40, IL-8 and Il-1alpha in Detroit 562 cell line. By using annexin-V apoptosis detection kit, we have found that poly I:C triggers apoptosis in Detroit 562 cell line. We have found here that based on the results of TLR3 functionality there is a huge difference between FaDu and Detroit 562 cell lines which are of the same origin (pharynx) but FaDu is primary and Detroit 562 metastatic carcinoma. Our study also shows that Detroit 562 cell line could be a good model for cancer therapy research and development as it is responsive to TLR3 agonists which consequently drives it to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19522763     DOI: 10.1111/j.1365-3083.2009.02262.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  14 in total

Review 1.  Mucins and toll-like receptors: kith and kin in infection and cancer.

Authors:  Shikha Tarang; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-02-03       Impact factor: 8.679

Review 2.  Mechanisms and pathways of innate immune activation and regulation in health and cancer.

Authors:  Jun Cui; Yongjun Chen; Helen Y Wang; Rong-Fu Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  The dual role of TLR3 in metastatic cell line.

Authors:  Tanja Matijevic; Jasminka Pavelic
Journal:  Clin Exp Metastasis       Date:  2011-07-07       Impact factor: 5.150

4.  Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA.

Authors:  Naoki Umemura; Jianzhong Zhu; Yvonne K Mburu; Adriana Forero; Paishiun N Hsieh; Ravikumar Muthuswamy; Pawel Kalinski; Robert L Ferris; Saumendra N Sarkar
Journal:  Cancer Res       Date:  2011-11-04       Impact factor: 12.701

Review 5.  Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?

Authors:  Li Yu; Liantang Wang; Shangwu Chen
Journal:  Cell Mol Life Sci       Date:  2011-11-03       Impact factor: 9.261

Review 6.  Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Chao-Qun Liu; Ying-Xiang Yang; Ping Lu; Shan-Feng Fu; Hui-Bin Qiu; Anthony E T Yeo
Journal:  J Biomed Biotechnol       Date:  2010-07-05

7.  Association between Toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma.

Authors:  Irene Russo; Camilla Cona; Andrea Saponeri; Franco Bassetto; Vincenzo Baldo; Mauro Alaibac
Journal:  Biomed Rep       Date:  2016-02-15

8.  Poly(I:C) treatment influences the expression of calreticulin and profilin-1 in a human HNSCC cell line: a proteomic study.

Authors:  Tanja Matijević; Jasminka Pavelić
Journal:  Tumour Biol       Date:  2012-03-14

9.  Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer.

Authors:  Wagner J Fávaro; Odilon S Nunes; Fabio Rf Seiva; Iseu S Nunes; Lisa K Woolhiser; Nelson Durán; Anne J Lenaerts
Journal:  Infect Agent Cancer       Date:  2012-06-18       Impact factor: 2.965

10.  Decreased expression of Toll-like receptor 4 and 5 during progression of prostate transformation in transgenic adenocarcinoma of mouse prostate mice.

Authors:  Ju-Hee Han; Jong-Hwan Park; Bo-Yeon Kim; Seo-Na Chang; Tae-Hyoun Kim; Jae-Hak Park; Dong-Jae Kim
Journal:  J Vet Sci       Date:  2015-03-20       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.